In breast cancer, also CD8+ cytotoxic T cells induce EMT, specifically during relapse and loss of a HER2/neu antigen‐mediated response, resulting in a more stem cell‐like phenotype with increased therapy resistance (Kmieciak et al, 2007; Santisteban et al, 2009). The gene discussed is ERBB2; the disease is breast carcinoma.